Long-term cytogenetic remission with ubenimex monotherapy in a case of chronic myeloid leukemia.
A 65-year-old man was diagnosed with chronic myeloid leukemia (CML) in February 1990, and was treated with busulfan and ubenimex. Cytogenetic analysis of the bone marrow revealed the Philadelphia (Ph) chromosome in 100% of cells of analyzed at diagnosis. Treatment with busulfan was stopped in March 1993 due to bone marrow suppression. The Ph chromosome was seen in 80% of cells in June 1993. He received ubenimex monotherapy after cessation of busulfan. Complete disappearance of the Ph chromosome was confirmed in May 1995 and has continued to date. This suggests that ubenimex might specifically affect the Ph chromosome and be useful as maintenance therapy for CML.
Kanamori
Heiwa
H
First Department of Internal Medicine, Yokohama City University School of Medicine, Kanazawa-ku, Yokohama, Japan. heiwak@med.yokohama-cu.ac.jp
Takasaki
Hirotaka
H
Takabayashi
Maki
M
Yamaji
Satoshi
S
Koharazawa
Hideyuki
H
Fujimaki
Katsumichi
K
Taguchi
Jun
J
Ishigatsubo
Yoshiaki
Y
D000368:Aged; D001854:Bone Marrow Cells / Q000187:drug effects / Q000473:pathology; D002066:Busulfan / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007930:Leucine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D010677:Philadelphia Chromosome; D012074:Remission Induction; D013997:Time Factors
D007155:Immunologic Factors; D002066:Busulfan; D007930:Leucine; C012211:ubenimex